Peripheral Blood Lymphocyte Subsets as a Risk Predictor of Patients with Endometrioid Endometrial Cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Li B, Wan X. Prognostic significance of immune landscape in tumor microenvironment of endometrial cancer. J Cell Mol Med. 2020;24(14):7767–7777. doi:10.1111/jcmm.15408
   PubMed Web of Science ®Google Scholar
• Bellone S, Centritto F, Black J, et al. Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecol Oncol. 2015;138(1):11–17. doi:10.1016/j.ygyno.2015.04.027
   PubMed Web of Science ®Google Scholar
• Pascual-García M, Bértolo C, Nieto JC, et al. CD8 down-regulation on cytotoxic T lymphocytes of patients with endometrioid endometrial carcinomas. Hum Pathol. 2016;56:180–188. doi:10.1016/j.humpath.2016.05.025
   PubMed Web of Science ®Google Scholar
• Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding: endometrial thickness and cancer risk. Ultrasound Obstetr Gynecol. 2004;24(5):558–565. doi:10.1002/uog.1704
   PubMed Web of Science ®Google Scholar
• Xia Y, Li W, Li Y, et al. The clinical value of the changes of peripheral lymphocyte subsets absolute counts in patients with non-small cell lung cancer. Transl Oncol. 2020;13(12):100849. doi:10.1016/j.tranon.2020.100849
   PubMed Web of Science ®Google Scholar
• Emons G, Vordermark D. Adjuvant treatment for endometrial cancer:. Curr Opin Oncol. 2019;31(5):404–410. doi:10.1097/CCO.0000000000000558
   PubMed Web of Science ®Google Scholar
• Lu M, Zheng J, Xu N, et al. Postoperative chemotherapy as adjuvant treatment for endometrioid adenocarcinoma: early stage vs late stage. Cancer Chemother Pharmacol. 2019;84(2):299–305. doi:10.1007/s00280-019-03847-w
   PubMed Web of Science ®Google Scholar
• Bohîlțea R, Ancăr V, Rădoi V, et al. Project for the national program of early diagnosis of endometrial cancer part II. J Med Life. 2015;8(4):423–431.
   PubMedGoogle Scholar
• Braun MM. Diagnosis and management of endometrial cancer. Endometrial Cancer. 2016;93(6):7.
   Google Scholar
• Lorenzo-Herrero S, López-Soto A, Sordo-Bahamonde C, et al. NK cell-based immunotherapy in cancer metastasis. Cancers. 2018;11(1):29. doi:10.3390/cancers11010029
   PubMed Web of Science ®Google Scholar
• Vgenopoulou S, Lazaris AC, Markopoulos C, et al. Immunohistochemical evaluation of immune response in invasive ductal breast cancer of not-otherwise-specified type. Breast. 2003;12(3):172–178. doi:10.1016/S0960-9776(03)00004-3
   PubMed Web of Science ®Google Scholar
• Somayeh R, Safaei A, Talei A, et al. NK, NKT and invariant-NKT cells in tumor draining lymph nodes of patients with breast cancer. Iran J Immunol. 2019;16(4):291–298.
   PubMed Web of Science ®Google Scholar
• Rezaeifard S, Talei A, Shariat M, et al. Tumor infiltrating NK cell (TINK) subsets and functional molecules in patients with breast cancer. Mol Immunol. 2021;136:161–167. doi:10.1016/j.molimm.2021.03.003
   PubMed Web of Science ®Google Scholar
• Zhang S, Minaguchi T, Xu C, et al. PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas. BMC Cancer. 2020;20(1):127. doi:10.1186/s12885-020-6545-9
   PubMed Web of Science ®Google Scholar
• Guo F, Dong Y, Tan Q, et al. Tissue infiltrating immune cells as prognostic biomarkers in endometrial cancer: a meta-analysis. Dis Markers. 2020;2020:1–11. doi:10.1155/2020/1805764
   Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991–998. doi:10.1038/ni1102-991
   PubMed Web of Science ®Google Scholar
• O’Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol. 2022;2022:JCO2101874.
   Google Scholar
• Bacalbasa N, Diaconu C, Iliescu L, et al. The influence of the metabolic syndrome on early postoperative outcomes of patients with advanced-stage endometrial cancer. In Vivo. 2020;34(5):2913–2917. doi:10.21873/invivo.12120
   PubMed Web of Science ®Google Scholar
• Kokts-Porietis RL, McNeil J, Nelson G, et al. Prospective cohort study of metabolic syndrome and endometrial cancer survival. Gynecol Oncol. 2020;158(3):727–733. doi:10.1016/j.ygyno.2020.06.488
   PubMed Web of Science ®Google Scholar
• Reijnen C, Visser NC, Kasius JC, et al. Improved preoperative risk stratification with CA-125 in low-grade endometrial cancer: a multicenter prospective cohort study. J Gynecol Oncol. 2019;30(5):e70. doi:10.3802/jgo.2019.30.e70
   PubMed Web of Science ®Google Scholar
• Knific T, Osredkar J, Smrkolj Š, et al. Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer. Gynecol Oncol. 2017;147(1):126–132. doi:10.1016/j.ygyno.2017.07.130
   PubMed Web of Science ®Google Scholar
• Yasin HK, Taylor AH, Ayakannu T. A narrative review of the role of diet and lifestyle factors in the development and prevention of endometrial cancer. Cancers. 2021;13(9):2149. doi:10.3390/cancers13092149
   PubMed Web of Science ®Google Scholar
• Showe MK, Kossenkov AV, Showe LC. The peripheral immune response and lung cancer prognosis. OncoImmunology. 2012;1(8):1414–1416. doi:10.4161/onci.21096
   PubMed Web of Science ®Google Scholar